Search

Your search keyword '"Benchetrit, Sydney"' showing total 327 results
Start Over Author "Benchetrit, Sydney"
327 results on '"Benchetrit, Sydney"'

30. Neutrophil reactive oxygen formation, bacterial infections and mortality in malnourished hemodialysis patients: Evaluation of clinical outcomes.

Author

Mudrik‐Zohar, Hadar, Alon, Danny, Nacasch, Naomi, Sternschuss, Aviad, Greenberg, Meidad, Benchetrit, Sydney, Gavrieli, Ronit, Zitman‐Gal, Tali, and Cohen‐Hagai, Keren

Subjects
REACTIVE oxygen species, HEMODIALYSIS patients, BACTERIAL diseases, MYOCARDIAL ischemia, ELECTRONIC health records
Abstract

Introduction: Patients with end stage kidney disease undergoing maintenance hemodialysis (MHD) are prone to malnutrition and infections. Objective: The objective of this study was to evaluate the effect of polymorphonuclear (PMN) cell dysfunction on clinical outcomes of MHD patients, in association with nutritional status. Methods: This prospective study investigated 39 MHD patients by evaluating the oxidative activity of their PMN cells using Phorbol 12‐Myristate‐13‐Acetate (PMA) stimulation. Blood samples were taken from each participant at dialysis initiation. Demographics, laboratory data, and clinical outcomes during a 24‐month follow‐up period were obtained from electronic medical records. Results: Phagocytic activity was described in percentiles of mean fluorescence intensity (MFI) of PMA levels. There were no differences in comorbidities between patients with low or high MFI‐PMA percentiles. Patients in the lowest (25th) MFI‐PMA percentile (N = 10) had poorer nutritional status and more frequent severe infections compared to the other 29 patients (4.3 ± 3.4 events versus 2 ± 2.2 events, p = 0.017). Furthermore, they had more frequent hospitalizations (>3) due to infections (70% versus 41%, p = 0.073) and their mortality rate was higher (80% versus 31%, p = 0.007). The odds ratio for all‐cause mortality was 8.85. In multivariate analysis, the MFI‐PMA percentile and ischemic heart disease were the strongest predictors of all‐cause mortality (p = 0.02 and p = 0.005, respectively). Conclusions: Low MFI‐PMA levels were associated with poor nutritional status and adverse clinical outcomes and might serve as a prognostic biomarker, predicting severe infections and mortality among malnourished MHD patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Humoral Response to Hepatitis B and COVID-19 Vaccine among Maintenance Hemodialysis Patients

Author

Nacasch, Naomi, primary, Cohen-Hagai, Keren, additional, Tayar, Nurit, additional, Levian, Avraham, additional, Rashid, Gloria, additional, Benchetrit, Sydney, additional, Neumark, Eran, additional, Wand, Ori, additional, Hod, Tammy, additional, Rosman, Yossi, additional, Shashar, Moshe, additional, Grupper, Ayelet, additional, and Shitrit, Pnina, additional

Published
2022
Full Text
View/download PDF

34. Kinetics of the humoral response 1-year following vaccination with BNT162b2 SARS-CoV-2 vaccine among maintenance hemodialysis patients

Author

Wand, Ori, primary, Einbinder, Yael, additional, Nacasch, Naomi, additional, Halperin, Tamar, additional, Erez, Daniel, additional, Grupper, Ayelet, additional, Benchetrit, Sydney, additional, Lishner, Michael, additional, Bar-Shai, Amir, additional, Shashar, Moshe, additional, and Cohen-Hagai, Keren, additional

Published
2022
Full Text
View/download PDF

37. Correction to: Comparison of long-term antibody response to mRNA SARS-CoV-2 vaccine among peritoneal dialysis and hemodialysis patients

Author

Einbinder, Yael, primary, Hornik-Lurie, Tzipi, additional, Cohen-Hagai, Keren, additional, Goldman, Shira, additional, Tanasiychuk, Tatiana, additional, Nacasch, Naomi, additional, Erez, Daniel, additional, Magen, Sophie, additional, Zitman-Gal, Tali, additional, Wiener-Well, Yonit, additional, Frajewicki, Victor, additional, Benchetrit, Sydney, additional, Shavit, Linda, additional, and Bnaya, Alon, additional

Published
2022
Full Text
View/download PDF

43. Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients

Author

Einbinder, Yael, primary, Perl, Jeffrey, additional, Nacasch, Naomi, additional, Bnaya, Alon, additional, Shavit, Linda, additional, Erez, Daniel, additional, Shashar, Moshe, additional, Halperin, Tamar, additional, Grupper, Ayelet, additional, Benchetrit, Sydney, additional, Wand, Ori, additional, and Cohen-Hagai, Keren, additional

Published
2022
Full Text
View/download PDF

44. Comparison of long-term antibody response to mRNA SARS-CoV-2 vaccine among peritoneal dialysis and hemodialysis patients

Author

Nacasch, Naomi, primary, Cohen-Hagai, Keren, additional, Benchetrit, Sydney, additional, Zitman-Gal, Tali, additional, Einbinder, Yael, additional, Erez, Daniel, additional, Hornik-Lurie, Tzipi, additional, Goldman, Shira, additional, Tanasiychuk, Tatiana, additional, Frajewicki, Victor, additional, Magen, Sophie, additional, Wiener-Well, Yonit, additional, Bnaya, Alon, additional, and Shavit, Linda, additional

Published
2021
Full Text
View/download PDF

50. Mortality prediction using a modified R2CHA2DS2-VASc score among hospitalized COVID-19 patients.

Author

Levy, David, Gur, Efrat, Topaz, Guy, Naser, Rawand, Kitay-Cohen, Yona, Benchetrit, Sydney, Sarel, Erez, Cohen-Hagai, Keren, and Wand, Ori

Abstract

The CHA2DS2-VASc score incorporates several comorbidities which have prognostic implications in COVID-19. We assessed whether a modified score (M-R2CHA2DS2-VASc), which includes pre-admission kidney function and male sex, could be used to classify mortality risk among people hospitalized with COVID-19. This retrospective study included adults admitted for COVID-19 between March and December 2020. Pre-admission glomerular filtration rate (GFR) was calculated based on serum creatinine and used for scoring M-R2CHA2DS2-VASc. Participants were categorized according to the M-R2CHA2DS2-VASc categories as 0–1 (low), 2–3 (intermediate), or ≥ 4 (high), and according to initial COVID-19 severity score. The primary outcome was 30-day mortality rates. Secondary outcomes were mortality rates over time, and rates of mechanical ventilation, hemodynamic support, and renal replacement therapy. Eight hundred hospitalizations met the study criteria. Participants were 55% males, average age was 65.2 ± 17 years. There were similar proportions of subjects across the M-R2CHA2DS2-VASc categories. 30-day mortality was higher in those in higher M-R2CHA2DS2-VASc category and with severe or critical COVID-19 at admission. Subjects in the low, intermediate, and high M-R2CHA2DS2-VASc categories had 30-day mortality rates of 4.7%, 17% and 31%, respectively (p < 0.001). Higher category was also associated with increased need for mechanical ventilation and renal replacement therapy. All-cause 90-day mortality remained significantly associated with M-R2CHA2DS2-VASc. The M-R2CHA2DS2-VASc score is associated with 30-day mortality rates among patients hospitalized with COVID-19, and adds predictive value when combined with initial COVID-19 severity. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results